ABLYNX'S PARTNER BOEHRINGER INGELHEIM PRESENTED POSITIVE IN VIVO PROOF-OF-MECHANISM DATA WITH BI-SPECIFIC NANOBODY AT EURO GLOBAL SUMMIT ON CANCER THERAPY
(Thomson Reuters ONE) -
* Bi-specific Nanobody demonstrates superior efficacy as compared to reference
monoclonal antibody drugs
* Bi-specific Nanobody strongly inhibits proliferation and survival of human
endothelial cells
GHENT, Belgium, 5 November 2015 - Ablynx [Euronext Brussels: ABLX; OTC: ABYLY]
today announced that its partner Boehringer Ingelheim presented positive in vivo
proof-of-mechanism data from the half-life extended bi-specific anti-VEGF/Ang2
Nanobody, at the 8(th) Euro Global Summit on Cancer Therapy, taking place 3-5
November 2015 in Valencia, Spain.
The anti-VEGF/Ang2 Nanobody was discovered and developed as part of the
Strategic Alliance between both parties, signed in September 2007. This Nanobody
blocks both vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang2),
important proteins which are involved in the formation of new blood vessels from
pre-existing vessels (angiogenesis), a vital mechanism in the growth of tumours.
The data was presented in a poster session by Boehringer Ingelheim on 4 November
2015 at 16.30h CET. Poster title: "Dual targeting of angiogenesis pathways:
combined blockade of VEGF and Ang2 signalling".
The results from the pre-clinical study demonstrated that this bi-specific
Nanobody potently inhibits VEGF and Ang2 signalling in multiple in vivo cancer
models and strongly impairs proliferation and survival of human endothelial
cells. In addition, the bi-specific Nanobody showed superior efficacy as
compared to inhibition of the individual pathways by the reference monoclonal
antibody drugs. The Nanobody was also found to be well tolerated in cynomolgus
monkeys.
These strong in vivo proof-of-mechanism results support the evaluation of this
Nanobody in Phase I clinical studies, which will trigger a milestone payment to
Ablynx at study start.
About Strategic Alliance between Boehringer Ingelheim and Ablynx
In September 2007, Ablynx and Boehringer Ingelheim entered into a strategic
alliance on the discovery, development and commercialisation of Nanobody
therapeutics across a range of diseases, including oncology, immunology,
respiratory and vascular diseases. The agreement allows for potential milestone
payments of up to ?125 million plus royalties to Ablynx for each Nanobody which
reaches the market. Boehringer Ingelheim is exclusively responsible for the
development, manufacturing and commercialisation of any products resulting from
the collaboration. Ablynx retains certain co-promotion rights in Europe. To
date, Ablynx has earned >?67 million in cash from this strategic alliance and in
addition to the anti-VEGF/Ang2 Nanobody there are a number of other programmes
advancing through pre-clinical development, all fully funded by Boehringer
Ingelheim.
About Ablynx
Ablynx is a biopharmaceutical company engaged in the development of Nanobodies®,
proprietary therapeutic proteins based on single-domain antibody fragments,
which combine the advantages of conventional antibody drugs with some of the
features of small-molecule drugs. Ablynx is dedicated to creating new medicines
which will make a real difference to society. Today, the Company has more than
30 proprietary and partnered programmes in development in various therapeutic
areas including inflammation, haematology, immuno-oncology, oncology and
respiratory disease. The Company has collaborations with multiple pharmaceutical
companies including AbbVie, Boehringer Ingelheim, Eddingpharm, Genzyme, Merck &
Co., Inc., Merck KGaA, Novartis and Taisho Pharmaceutical Co., Ltd. The Company
is headquartered in Ghent, Belgium. More information can be found on
www.ablynx.com.
For more information, please contact
Ablynx:
Dr Edwin Moses
CEO
t: +32 (0)9 262 00 07
m: +32 (0)473 39 50 68
e: edwin.moses(at)ablynx.com
Marieke Vermeersch
Associate Director Investor Relations
t: +32 (0)9 262 00 82
m: +32 (0)479 49 06 03
e: marieke.vermeersch(at)ablynx.com
Follow us on Twitter (at)AblynxABLX
Ablynx media relations Instinctif Partners:
Sue Charles, Daniel Gooch
London office
t: +44 (0)20 7866 7905
e: ablynx(at)instinctif.com
Belgium/Dutch and French language
Jim Rusagara
Brussels office
t: +32 (0)2 626 9500
e: ablynx(at)instinctif.com
pdf format of the press release:
http://hugin.info/137912/R/1964208/716883.pdf
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Ablynx via GlobeNewswire
[HUG#1964208]
Unternehmensinformation / Kurzprofil:
Datum: 05.11.2015 - 07:00 Uhr
Sprache: Deutsch
News-ID 432122
Anzahl Zeichen: 5514
contact information:
Town:
Ghent/Zwijnaarde
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 239 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"ABLYNX'S PARTNER BOEHRINGER INGELHEIM PRESENTED POSITIVE IN VIVO PROOF-OF-MECHANISM DATA WITH BI-SPECIFIC NANOBODY AT EURO GLOBAL SUMMIT ON CANCER THERAPY"
steht unter der journalistisch-redaktionellen Verantwortung von
Ablynx (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
